With $60M round, BreezeBio turns delivery platform into internal pipeline: Venture Report

A new $60 million series B round will fuel newly rechristened BreezeBio’s endeavor to turn its delivery platform into a pipeline of its own therapeutics, as its lead candidate for diabetes moves toward the clinic.

Known until early 2026 as GenEdit Inc., the company has been developing its NanoGalaxy polymer platform for delivery of genetic payloads to specific systems, including the CNS, cardiac, immune and pulmonary systems. The platform is the subject of an ongoing partnership with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), which has added non-dilutive funding to BreezeBio Inc.’s till, including a milestone payment...